Discovery of novel CDK2 inhibitor as antitumor agent based on Fragment-Based Drug Design
碩士 === 元智大學 === 資訊工程學系 === 104 === Cyclin Dependent Kinase (CDK) is one of regutators for adjusting the cell cycle. When the cycling of Cyclin Dependent Kinase (cdk) disorders can cause abnormal cell cycle regulation, this is one of the important causes of cancer tumors. Malignant tumor is a cause...
Main Authors: | Kuang-Hao Cheng, 鄭光浩 |
---|---|
Other Authors: | Tzong-Yi Lee |
Format: | Others |
Language: | zh-TW |
Published: |
2016
|
Online Access: | http://ndltd.ncl.edu.tw/handle/s8y4r9 |
Similar Items
-
NMR in drug discovery. From screening to structure-based design of antitumoral agents
by: Rodríguez Mías, Ricard Aleix
Published: (2006) -
Discovery of a Novel Acetylcholinesterase Inhibitor by Fragment-Based Design and Virtual Screening
by: Georgi Stavrakov, et al.
Published: (2021-04-01) -
Discovery and antitumor evaluation of novel inhibitors of spermine oxidase
by: Lidan Sun, et al.
Published: (2019-01-01) -
Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent
by: Liu W, et al.
Published: (2015-07-01) -
Purine-based dual inhibitors of CDK2 and CDK7
by: Meschini, Elisa
Published: (2011)